Revised Outcome of the Board Meeting dated 05th November, 2026

Date: 05th November, 2026 BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street - Fort, Mumbai — 400 001. Ref.: BSE Scrip Code - 539730 Subject: Revised Outcome of the Board Meeting Dear Sir / Madam, Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 05, 2026 has inter-alia, considered, adopted and approved following items of business: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter and Half-Year Ended 30th September, 2026 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditor of the Company; copies of which are attached hereunder; 2. The Board considered and approved the proposal for making an application to National Stock Exchange of India Limited (NSE) for listing and trading of the equity shares of the Company on NSE, subject to applicable laws, regulations and the necessary approvals. In furtherance to the intimation filed by the Company dated September 28, 2026 the trading window for trading in securities of the Company by insiders closed on October 01, 2026 till the end of 48 hours after the declaration of outcome of this Board Meeting. The Board Meeting commenced at 10:00 a.m. and concluded at 11:10 a.m. Kindly oblige and take the same on your Records. Thanking you, FOR FREDUN PHARMACEUTICALS LIMITED FREDUN NARIMAN MEDHORA MANAGING DIRECTOR DIN: 01745348 rREDU" PHARMACEUTICALS L.IMITED Compassion ale Jlealihcare CIN No: L24239MH1987PLC043662 FREDUN PHARMACEUTICALS LIMITED Standalone Balance Sheet for the Half Year Ended 30th Sept, 2026 ( Amount In Lakhs ) Notes As at 30th Sept, 2026 As at 31st March, 2026 I ASSETS NON-CURRENT ASSETS a) Property, Plant and Equipment 3 14,825.90 11,760.54 b) Other Intangible Assets 4 69.42 62.94 c) F'inancial assets i) Investments 5 254.23 201.73 ii) Other F'inancial Assets 6 2,945.52 1,596.00 d) Other Non-current Assets 7 2,649.10 805.04 Total non -current assets 20,744.16 14,426.25 CURRENT ASSETS a) Inventories 8 37,244.77 26,980.45 b) Financial Assets i) Trade and other receivables 9 9,703.33 9,268.52 ii) Cash and Cash Equivalents 10 5,515.14 6,490.41 iii) Bank Balance other than (iii) above 11 5.43 4.91 iv) Loans 12 124.03 99.78 v) Other F'inancial Assets 13 l,317.17 5,325.71 c) Other Current Assets 14 2,146.23 1 ,525.34 Total current assets 56,056.11 49,695.11 TOTAL ASSESTS 76,800.27 64,121.36 II EQUITY AND LlABIL.ITIES EQUITY a) Equity share rapital 15 1,689.97 547.27 b) Other equity 16 31,442.00 27,323.90 Total Equity 33,131.96 27,871.17 LlABILITIES Non-Current Liabilities a) Financial liabililjcs i) 9orrowings 17 8,693.39 ·--5 ·,631 -.03 b) Provisions 18 418.46 425.55 c) Deferred Tex Liability 1,127.45 654.80 Total non current -liabilities 10,239.30 6,711.37 Current Liabilities a) Financial liabilities i) Borrowings 19 15,971.46 16,572.03 ii) Trade and other payable 20 12,231.72 8,746.68 iii) Other financial liabilities 21 5.43 4.85 b) Other current liabilities 22 3,903.41 3,26 ·. -. 19 c) Current lax liabilibes (net) 23 1,317.00 ·9-54.07 Total current liabilities 33,429.01 29,538.82 TOTAL EQUITY & LlABlLlTIES 76,800.27 64,121.36 Pharmaceuticals Limited ~ ~ CIN No -L24239MH1987PLC043662 ~~/ i:0: '"' •re<oo » •rmooooUoo» '"""•' Place -Mumbai Dr. (Mrs) Daulat N.Medhora I· Date :- 05th November 2026 Joint Managing Director Managing Director & CFO Registered Office: Urmi Estate, 11th Floor, Ganpatrao KadanPMar,,11.'.U'N@rrParel (W), Mumbat-u~OOITT1~348 Phone No.: 91-22-4031 8111 Fax: 91-22-4031 8133 Factory: 14, 15, 16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar-401 404. Phone No.: +917045957828, +917045957829, +917045957830, +917045956857 E-Mail: business@fredungroup.com Web: www.fredungroup.com R.H.Nisar & Co. Chartered Accountant A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089 Contact No: 9867351724, Email – rakesh.nisar1@gmail.com Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Fredun Pharmaceuticals Limited, 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Company') for the quarter ended 30th September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors on 05th November, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. R.H.Nisar & Co. Chartered Accountant A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089 Contact No: 9867351724, Email – rakesh.nisar1@gmail.com 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion on the statement is not modified in respect of the above matter. FOR R H NISAR & CO. CHARTERED ACCOUNTANTS FIRM’S REGISTRATION NUMBER: 120895W RAKESH NISAR PROPRIETOR MEMBERSHIP NO. 103659 UDIN: 26103659CBPFCW2224 PLACE: MUMBAI DATE: 5th November, 2026 R.H.Nisar & Co. Chartered Accountant A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089 Contact No: 9867351724 Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Fredun Pharmaceuticals Limited, 1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Parent') and its subsidiaries (the Parent and its subsidiaries togethe [Showing first 8,000 characters — download PDF for full document]